News and resources | Resources
Video 15 October 2020

2020: a game changer year for AMR? (Video)

By IFPMA
Share
Topics
Antimicrobial resistance

At the AMR Congress 2020, Dame Sally Davies, UK AMR Special Envoy asked Thomas Cueni, IFPMA’s Director General, if industry has done enough to tackle AMR and what remains to be done to create a sustainable market and long-term R&D investment into antibiotics.

About IFPMA

The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) represents over 90 innovative pharmaceutical companies and associations across the globe. Based in Geneva, IFPMA has official relations with the United Nations and contributes industry expertise to help the global health community improve the lives of people everywhere. The industry’s two million employees discover, develop, and deliver medicines and vaccines that advance global health.

Learn more

Media Contact

Abigail Jones

Related news and resources

Statement 17 Mar 2023

WHO Intergovernmental Negotiating Body (INB) intersessional briefing on “One Health and the Quadripartite”

On 17 March, IFPMA delivered a shortened version of the below statement at the WHO INB intersessional briefing on “Article 18: One Health and the Quadripartite” of the WHO convention, agreement, or other international instrument on pandemic prevention, preparedness, and response (“WHO CA+”).

Read more
Statement 12 Apr 2022

IFPMA comment on draft guidance on value of new antibiotics as part of UK “subscription-type” payment model

Geneva, April 12 2022 – Commenting on the publication of draft guidance from the National  Institute for Health and Care Excellence (NICE) on antimicrobial drugs to become available as part of the UK’s innovative ‘subscription-type’ payment model, Thomas Cueni, IFPMA Director-General, said: “We welcome the results of the UK work to reward the full value...

Read more
Press release 4 Apr 2022

Largest pharmaceutical industry-backed collective venture fund tackling antimicrobial resistance announces first portfolio investments

April 4, 2022, Geneva – The international trade body representing the biopharmaceutical industry (IFPMA) today welcomes the announcement of the AMR Action Fund’s first portfolio investments. The Fund is the world’s largest public-private partnership investing in biotech companies that are developing antibiotics, involving more than 20 leading biopharmaceutical companies who raised the majority of the...

Read more
Top